



- (51) **International Patent Classification:**
A61F 2/86 (2013.01)
- (21) **International Application Number:**
PCT/US2014/026984
- (22) **International Filing Date:**
14 March 2014 (14.03.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
13/833,588 15 March 2013 (15.03.2013) US
- (71) **Applicant:** MEDTRONIC VASCULAR INC. [US/US];
c/o IP Legal Department, 3576 Unocal Place, Santa Rosa,
California 95403 (US).
- (72) **Inventor:** THOMPSON, Dustin; c/o IP Legal Depart-
ment, Medtronic Vascular Inc., 3576 Unocal Place, Santa
Rosa, California 95403 (US).
- (74) **Agent:** RUSCHKE, David P.; c/o IP Legal Department,
Medtronic Vascular Inc., 3576 Unocal Place, Santa Rosa,
California 95403 (US).
- (81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

- (84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) **Title:** WELDED STENT AND STENT DELIVERY SYSTEM




FIG. 1

(57) **Abstract:** A welded stent and stent delivery system, with a stent including a first strut having a first strut nickel titanium alloy layer and nickel titanium soluble core, the first strut nickel titanium alloy layer being disposed around the first strut nickel titanium soluble core; and a second strut having a second strut nickel titanium alloy layer and nickel titanium soluble core, the second strut nickel titanium alloy layer being disposed around the second strut nickel titanium soluble core, the second strut nickel titanium alloy layer being connected to the first strut nickel titanium alloy layer with a weld. The first and second strut nickel titanium alloy layers are made of a nickel titanium alloy, the first and second strut nickel titanium soluble cores are made of a nickel titanium soluble material, and the weld is made of an alloy of the nickel titanium alloy and the nickel titanium soluble material.



WELDED STENT AND STENT DELIVERY SYSTEM

TECHNICAL FIELD

[0001] The technical field of this disclosure is medical implant devices, particularly, welded stents and stent delivery systems.

BACKGROUND OF THE INVENTION

[0002] Stents are generally cylindrical shaped devices that are radially expandable to hold open a segment of a blood vessel or other anatomical lumen after implantation into the body lumen. Stents have been developed with coatings to deliver drugs or other therapeutic agents.

[0003] Stents are used in conjunction with balloon catheters in a variety of medical therapeutic applications including intravascular angioplasty. For example, a balloon catheter device is inflated during PTCA (percutaneous transluminal coronary angioplasty) to dilate a stenotic blood vessel. The stenosis may be the result of a lesion such as a plaque or thrombus. After inflation, the pressurized balloon exerts a compressive force on the lesion thereby increasing the inner diameter of the affected vessel. The increased interior vessel diameter facilitates improved blood flow. Soon after the procedure, however, a significant proportion of treated vessels re-narrow.

[0004] To prevent restenosis, short flexible cylinders, or stents, constructed of metal or various polymers are implanted within the vessel to maintain lumen size. The stents acts as a scaffold to support the lumen in an open position. Various configurations of stents include a cylindrical tube defined by a mesh, interconnected stents or like segments. Some exemplary stents are disclosed in U.S. Patent No. 5,292,331 to Boneau, U.S. Patent No. 6,090,127 to Globerman, U.S. Patent No. 5,133,732 to Wiktor, U.S. Patent No. 4,739,762 to Palmaz and U.S. Patent No. 5,421,955 to Lau. Balloon-expandable stents are mounted on a collapsed balloon at a diameter smaller than when the stents are deployed. Stents can also be self-expanding, growing to a final diameter when deployed without mechanical assistance from a balloon or like device.

[0005] Stents can currently be made of nitinol, which is a nickel titanium alloy. The shape memory and super elastic properties of nitinol are useful in medical devices. Unfortunately, nitinol is difficult to weld because nitinol forms an oxide layer on its surface that makes it difficult for the melt of the weld pool to reach the base metal during the

welding process and achieve a good weld. Further, nitinol welds tend to be brittle, increasing the chance of weld failure. Welding difficulties can increase stent manufacturing costs due to increased manufacturing time and added quality control requirements. Poor welds can also decrease the performance of stents in use should the welds fail after implantation in the patient.

[0006] Other problems exist with drug eluting stents, which currently employ exterior coatings with or without polymers on metal struts to hold a drug for subsequent elution and delivery of the drug to surrounding tissue. Unfortunately, the coatings can be fragile and can fracture and fragment during manufacture, delivery, deployment, or use. Fracture during manufacture increases the cost and complexity of manufacture. Fracture during delivery, deployment, or use can reduce the effectiveness of the stent due to lost drug and can pose a risk to the patient if fragments block blood flow. The drug elutes from the coating surface, so the duration of drug elution is limited by the coating thickness, i.e., the mean diffusion length of the drug within the polymer coating. Concerns have also been raised over the long-term effects of polymers in contact with the body.

[0007] It would be desirable to have a welded stent and stent delivery system that would overcome the above disadvantages.

SUMMARY OF THE INVENTION

[0008] One aspect of the invention provides a stent delivery system including a catheter; a sheath disposed around the catheter; and a stent disposed on the catheter. The stent forms a tubular body and includes: a first strut, the first strut having in transverse cross section a first strut nickel titanium alloy layer and a first strut nickel titanium soluble core, the first strut nickel titanium alloy layer being disposed around and immediately adjacent to the first strut nickel titanium soluble core; and a second strut, the second strut having in transverse cross section a second strut nickel titanium alloy layer and a second strut nickel titanium soluble core, the second strut nickel titanium alloy layer being disposed around and immediately adjacent to the second strut nickel titanium soluble core, the second strut nickel titanium alloy layer being connected to the first strut nickel titanium alloy layer with a weld. The first strut nickel titanium alloy layer and the second strut nickel titanium alloy layer are made of a nickel titanium alloy, the first strut nickel titanium soluble core and the second strut nickel titanium soluble core are made of a nickel titanium soluble material, the weld is made of an alloy of the nickel titanium alloy and the nickel titanium soluble material, and the

weld further connects the first strut nickel titanium soluble core and the second strut nickel titanium soluble core.

[0009] Another aspect of the invention provides a stent forming a tubular body including a first strut, the first strut having in transverse cross section a first strut nickel titanium alloy layer and a first strut nickel titanium soluble core, the first strut nickel titanium alloy layer being disposed around and immediately adjacent to the first strut nickel titanium soluble core; and a second strut, the second strut having in transverse cross section a second strut nickel titanium alloy layer and a second strut nickel titanium soluble core, the second strut nickel titanium alloy layer being disposed around and immediately adjacent to the second strut nickel titanium soluble core, the second strut nickel titanium alloy layer being connected to the first strut nickel titanium alloy layer with a weld. The first strut nickel titanium alloy layer and the second strut nickel titanium alloy layer are made of a nickel titanium alloy, the first strut nickel titanium soluble core and the second strut nickel titanium soluble core are made of a nickel titanium soluble material, the weld is made of an alloy of the nickel titanium alloy and the nickel titanium soluble material, and the weld further connects the first strut nickel titanium soluble core and the second strut nickel titanium soluble core.

[0010] Another aspect of the invention provides a method of manufacturing a stent including providing a first strut having in transverse cross section a first strut nickel titanium alloy layer and a first strut nickel titanium soluble core, the first strut nickel titanium alloy layer being disposed around and immediately adjacent to the first strut nickel titanium soluble core, the first strut nickel titanium alloy layer being made of a nickel titanium alloy, the first strut nickel titanium soluble core being made of a nickel titanium soluble material; providing a second strut having in transverse cross section a second strut nickel titanium alloy layer and a second strut nickel titanium soluble core, the second strut nickel titanium alloy layer being disposed around and immediately adjacent to the second strut nickel titanium soluble core, the second strut nickel titanium alloy layer being made of the nickel titanium alloy, the second strut nickel titanium soluble core being made of the nickel titanium soluble material; positioning the first strut adjacent to the second strut at a weld point; at the weld point, melting portions of the first strut nickel titanium alloy layer, the first strut nickel titanium soluble core, the second strut nickel titanium alloy layer, and the second strut nickel titanium soluble core to form a weld pool including the nickel titanium alloy from the first strut nickel titanium alloy layer and the second strut nickel titanium alloy layer,

the weld pool further including the nickel titanium soluble material from the first strut nickel titanium soluble core and the second strut nickel titanium soluble core; and cooling the weld pool to form a weld connecting the first strut nickel titanium alloy layer to the second strut nickel titanium alloy layer.

[0011] The foregoing and other features and advantages of the invention will become further apparent from the following detailed description of the presently preferred embodiments, read in conjunction with the accompanying drawings. The detailed description and drawings are merely illustrative of the invention, rather than limiting the scope of the invention being defined by the appended claims and equivalents thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

[0012] FIG. 1 is a perspective view of a stent delivery system made in accordance with the invention.

[0013] FIG. 2 is a side view of a welded stent made in accordance with the invention.

[0014] FIG. 3 is a transverse cross section view of a weld region of a welded stent made in accordance with the invention.

[0015] FIGS. 4A-4C are transverse cross section views of a weld region in a method of manufacture of a welded stent in accordance with the invention.

[0016] FIG. 5 is a flow chart of a method of manufacture of a welded stent in accordance with the invention.

DETAILED DESCRIPTION

[0017] FIG. 1 is a perspective view of a stent delivery system made in accordance with the invention. The stent delivery system 100 includes a catheter 105, a sheath 102 disposed around the catheter 105, and a stent 120 disposed on the catheter 105. In this embodiment, the stent 120 is a self-expanding stent. FIG. 1 illustrates the stent delivery system 100 with the stent 120 expanded and deployed after the sheath 102 has been retracted or the catheter 105 has been advanced. Before the stent 120 is deployed, the stent 120 is disposed on the catheter 105 within the sheath 102. The stent 120 is operable for use in a vessel having a vessel wall forming a vessel lumen. The stent 120 is a welded stent in which one or more struts interconnect to form a tubular body. In one embodiment, the stent delivery system 100 can include retention means 111, such as mechanical or adhesive structures, for retaining the stent 120 on the catheter 105 until the stent 120 is deployed.

[0018] **FIG. 2** is a side view of a welded stent made in accordance with the invention. The stent includes one or more struts interconnected to form a tubular body. The stent can include a first strut having in transverse cross section a first strut nickel titanium alloy layer and a first strut nickel titanium soluble core, with the first strut nickel titanium alloy layer being disposed around and immediately adjacent to the first strut nickel titanium soluble core. The stent can further include a second strut having in transverse cross section a second strut nickel titanium alloy layer and a second strut nickel titanium soluble core, with the second strut nickel titanium alloy layer being disposed around and immediately adjacent to the second strut nickel titanium soluble core. The second strut nickel titanium alloy layer of the second strut can be connected to the first strut nickel titanium alloy layer of the first strut with a weld. The first strut nickel titanium alloy layer and the second strut nickel titanium alloy layer are made of a nickel titanium alloy, and the first strut nickel titanium soluble core and the second strut nickel titanium soluble core are made of a nickel titanium soluble material. The weld is made of an alloy of the nickel titanium alloy (from the first strut nickel titanium alloy layer and the second strut nickel titanium alloy layer) and the nickel titanium soluble material (from the first strut nickel titanium soluble core and the second strut nickel titanium soluble core). In one embodiment, the weld further connects the first strut nickel titanium soluble core and the second strut nickel titanium soluble core. The stent **120** can be installed in the stent delivery system of **FIG. 1** for implantation in a body lumen, such as a vessel lumen. In one embodiment, the stent **120** can be self-expanding. In another embodiment, the stent **120** can be expanded by a balloon or another device. When the stent **120** is balloon-expanded, the catheter **105** may be any variety of balloon catheters, such as a PTCA (percutaneous transluminal coronary angioplasty) balloon catheter, capable of supporting a balloon during angioplasty.

[0019] Referring to **FIG. 2**, the stent **120** includes a number of struts **130** interconnected to form the tubular body of the stent **120**. The stent **120** includes at least one opening **132** and has a central axis **134** with the openings **132** around the central axis. In one embodiment, the struts **130** can be separate continuous sinusoidal rings encircling the central axis **134**, with the peaks of the sinusoidal rings welded together at weld regions **136** where adjacent sinusoidal rings intersect. In another embodiment, the struts **130** can be part of a single sinusoidal wire which spirals around the central axis **134**, with the peaks of the single sinusoidal wire welded together at weld regions **136** where adjacent turns of the sinusoidal

wire intersect. The pattern of the struts **130** can be W-shaped or can be a more complex shape with the elements of one segment continuing into the adjacent segment.

[0020] Those skilled in the art will appreciate that drugs or other therapeutic agents can be applied to the stent **120** for release once the stent is implanted. In one embodiment, an outer drug coating (not shown) can be disposed on at least one of the struts. In one embodiment, the struts can be hollow and filled with one or more drugs or other therapeutic agents, which can be released through perforations (not shown) between the drug-filled central void and the exterior of the struts.

[0021] The cross section A-A of an exemplary weld region **138** in **FIG. 2** with first strut **140** and second strut **150** is illustrated in detail in **FIG. 3**, which is a transverse cross section view of a weld region of a welded stent made in accordance with the invention.

[0022] Referring to **FIG. 3**, the first strut **140** includes a nickel titanium alloy layer **142** and a nickel titanium soluble core **144**. The nickel titanium alloy layer **142** is disposed around and immediately adjacent to the nickel titanium soluble core **144**. Similarly, the second strut **150** includes a nickel titanium alloy layer **152** and a nickel titanium soluble core **154**. The nickel titanium alloy layer **152** is disposed around and immediately adjacent to the nickel titanium soluble core **154**. The nickel titanium alloy layer **142** of the first strut **140** is connected to the nickel titanium alloy layer **152** of the second strut **150** with weld **160**.

Those skilled in the art will appreciate that the transverse cross section of the struts **140**, **150** is not limited to the circular cross section illustrated but can be any cross section (e.g., square, rectangular, ellipsoid, or the like) as desired for a particular application. The dimensions of the nickel titanium alloy layers and the nickel titanium soluble cores can be selected in light of a variety of considerations, such as strut stiffness, weld composition, weldability, and the like. In one example, the strut outer diameter can be in the range of 0.002–0.010 inches. In one example, the thickness of the nickel titanium alloy layer can be in the range of 0.0005–0.004 inches. In one particular example, the strut outer diameter can be 0.007 inches, the diameter of nickel titanium soluble core can be 0.0022 inches, and the thickness of the nickel titanium alloy layer can be 0.0024 inches.

[0023] The weld **160** is formed from melting together portions of the nickel titanium alloy layers **142**, **152** and the nickel titanium soluble cores **144**, **154**. The nickel titanium alloy layers **142**, **152** are made of a nickel titanium alloy, commonly known as nitinol. The nickel titanium soluble cores **144**, **154** are made of one or more nickel titanium soluble materials, which are defined herein as materials such as metals, mixtures, or alloys which are

soluble with a nickel titanium alloy melt during welding. Exemplary nickel titanium soluble materials include chromium, molybdenum, iron, and cobalt, singly or in combination as mixtures or alloys.

[0024] The nickel titanium soluble materials for the nickel titanium soluble cores **144**, **154** are selected to form a weld **160** having the desired strength and flexibility for a particular application. In one embodiment, the nickel titanium soluble material is molybdenum, which produces a weld of a nickel titanium molybdenum alloy. Exemplary nickel titanium molybdenum alloys can include nickel in the range of 45 to 55 percent, titanium in the range of 40 to 45 percent and molybdenum in the range of 5 to 10 percent. The molybdenum in the nickel titanium soluble core can be maintained in place or can be removed to generate a central void within the nickel titanium alloy layer. Optionally, the central void can be filled with a drug or other therapeutic agent to be released after deployment through perforations in the nickel titanium alloy layer between the drug-filled central void and the exterior of the struts. In another embodiment, the nickel titanium soluble material is a chromium molybdenum alloy, which produces a weld of a nickel titanium chromium molybdenum alloy, utilizing the same constituents as a commercially known alloy by the name of Hastelloy C4. Exemplary nickel titanium chromium molybdenum alloys can include nickel in the range of 60 to 70 percent, titanium in the range of 0.5 to 1.0 percent, chromium in the range of 14 to 18 percent and molybdenum in the range of 14 to 17 percent. Other exemplary nickel titanium soluble materials include chromium and iron, utilizing the same constituents as a commercially known alloy by the name of Nimonic 75 (Ni 20-Cr 5-Fe 0.6Ti), as well as chromium and cobalt, utilizing the same constituents as a commercially known alloy by the name of Nimonic 90 (Ni 20-Cr 18-Co 3-Ti). Those skilled in the art will appreciate that the nickel titanium soluble material for the nickel titanium soluble core can be selected as desired for a particular application. Those skilled in the art will further appreciate that many of the benefits of commercial alloys, such as Hastelloy C4, Nimonic 75, or Nimonic 90, can be achieved without requiring the exact constituent percentages of the commercial alloy.

[0025] **FIGS. 4A-4C**, in which like elements share like reference numbers, are transverse cross section views of a weld region in a method of manufacture of a welded stent in accordance with the invention.

[0026] **FIG. 4A** is a transverse cross section view of a weld region in a method of manufacture of a welded stent before welding. The first strut **240** includes a first strut nickel

titanium alloy layer **242** and a first strut nickel titanium soluble core **244**. The second strut **250** includes a second strut nickel titanium alloy layer **252** and a second strut nickel titanium soluble core **254**. The first strut **240** is positioned adjacent the second strut **250** at the weld point.

[0027] **FIG. 4B** is a transverse cross section view of a weld region in a method of manufacture of a welded stent during welding. Energy **270** is applied to the first strut **240** and the second strut **250** to melt portions of the nickel titanium alloy layers **242**, **252** and the nickel titanium soluble cores **244**, **254**, to form a weld pool **260**. The weld pool **260** is a mixture of nickel titanium alloy and nickel titanium soluble material in predetermined percentages to produce the alloy desired for the weld. The nickel titanium alloy layers **242**, **252** are made of a nickel titanium alloy, commonly known as nitinol. In one embodiment, the nickel titanium soluble cores **244**, **254** are made of molybdenum, so that the weld pool **260** is a mixture of nickel, titanium, and molybdenum. In another embodiment, the nickel titanium soluble cores **244**, **254** are made of a molybdenum chromium alloy, so that the weld pool **260** is a mixture of nickel, titanium, molybdenum, and chromium. Other exemplary nickel titanium soluble materials include chromium, molybdenum, iron, and cobalt, singly or in combination as mixtures or alloys. The welding parameters and the size of the weld pool can be controlled to form a weld pool that will produce the desired weld for a particular application. Exemplary welding methods include arc welding, laser welding, and resistance welding.

[0028] **FIG. 4C** is a transverse cross section view of a weld region in a method of manufacture of a welded stent after welding. The weld **262** forms from cooling of the weld pool **260**. The weld **262** connects the nickel titanium alloy layers **242**, **252** and can also connect the nickel titanium soluble cores **244**, **254**. In one embodiment, the nickel titanium soluble cores **244**, **254** can be removed to form central voids, which can be left hollow or filled with a drug or other therapeutic agent.

[0029] **FIG. 5** is a flow chart of a method of manufacture of a welded stent in accordance with the invention. The method of manufacturing a stent **300** includes providing a first strut **302** having in transverse cross section a first strut nickel titanium alloy layer and a first strut nickel titanium soluble core, the first strut nickel titanium alloy layer being disposed around and immediately adjacent to the first strut nickel titanium soluble core, the first strut nickel titanium alloy layer being made of a nickel titanium alloy, the first strut

nickel titanium soluble core being made of a nickel titanium soluble material; providing a second strut **304** having in transverse cross section a second strut nickel titanium alloy layer and a second strut nickel titanium soluble core, the second strut nickel titanium alloy layer being disposed around and immediately adjacent to the second strut nickel titanium soluble core, the second strut nickel titanium alloy layer being made of the nickel titanium alloy, the second strut nickel titanium soluble core being made of the nickel titanium soluble material; positioning the first strut adjacent to the second strut at a weld point **306**; at the weld point, melting portions of the first strut nickel titanium alloy layer, the first strut nickel titanium soluble core, the second strut nickel titanium alloy layer, and the second strut nickel titanium soluble core to form a weld pool **308** including the nickel titanium alloy from the first strut nickel titanium alloy layer and the second strut nickel titanium alloy layer, the weld pool further including the nickel titanium soluble material from the first strut nickel titanium soluble core and the second strut nickel titanium soluble core; and cooling the weld pool to form a weld **310** connecting the first strut nickel titanium alloy layer to the second strut nickel titanium alloy layer.

[0030] The providing a first strut **302** and the providing a second strut **304** includes providing struts with nickel titanium alloy layers disposed around nickel titanium soluble cores. In one embodiment, the first strut and second strut are part of separate continuous sinusoidal rings. In another embodiment, the first strut and second strut are part of a single sinusoidal wire.

[0031] The nickel titanium alloy layers and nickel titanium soluble cores of the struts provide the source material for welding the first strut to the second strut. The composition of the nickel titanium alloy layers and nickel titanium soluble cores can be selected to form a weld having the desired strength and flexibility for a particular application. The nickel titanium alloy layers are made of a nickel titanium alloy, commonly known as nitinol. Exemplary nickel titanium soluble cores can be made of molybdenum or a molybdenum-chromium alloy. Other exemplary nickel titanium soluble materials include chromium, iron, and cobalt, singly or in combination as mixtures or alloys. Particular exemplary combinations of nickel titanium soluble materials include chromium and iron, which produces a nickel titanium chromium iron weld, as well as chromium and cobalt, which produces a nickel titanium chromium cobalt weld. In one embodiment, the struts can include perforations through the walls of the struts between the central void and the exterior of the struts to permit removal of the nickel titanium soluble core from the central void

within the nickel titanium alloy layer and optionally to permit filling of the central void with a drug or therapeutic agent.

[0032] The positioning the first strut adjacent to the second strut at a weld point **306** can include positioning the struts with the assistance of a jig or other device to assist welding. Once welded, the struts of the stent form a tubular body. The first strut and the second strut can optionally be prepared for welding by cleaning, degreasing, or the like.

[0033] The melting portions of the strut nickel titanium alloy layers and the strut nickel titanium soluble cores to form a weld pool **308** can include selecting welding parameters, such as duration, temperature, energy deposition, and the like, to form a suitable weld pool for the particular application, depending on the materials of the strut nickel titanium alloy layers and the strut nickel titanium soluble cores. The size of the weld pool can be controlled to melt a desired amount of material from the strut nickel titanium alloy layers and the strut nickel titanium soluble cores to form a weld pool and subsequent weld of the desired composition. Suitable welding methods include arc welding, laser welding, and resistance welding.

[0034] The cooling the weld pool to form a weld **310** can include controlling cooling rate and annealing the weld to form the desired phase and crystalline structure in the weld. In one embodiment, the nickel titanium soluble core of the first strut is connected to the nickel titanium soluble core of the second strut by the weld.

[0035] The method of manufacturing a stent **300** can further include removing the first strut nickel titanium soluble core to form a first strut central void, which can be left hollow as a central void or filled with a drug or other therapeutic agent. The nickel titanium soluble cores can be removed in one or more of the struts, or all of the struts. When the nickel titanium soluble material is molybdenum, xenon difluoride can be used to vaporize and remove the molybdenum. In one example, a core of molybdenum reacts with xenon difluoride (XeF_2) gas at low pressure (1-6 Torr) and relatively high temperature (approximately 150° C) to form molybdenum hexafluoride (MoF_6) and xenon (Xe) gases, which can be exhausted to form a central void within the strut nickel titanium alloy layer. In one embodiment, the xenon difluoride is introduced to the molybdenum through perforations in the wall of the strut nickel titanium alloy layer, and the resulting molybdenum hexafluoride and xenon gases exhaust through the perforations to the exterior of the struts. In another embodiment, the xenon difluoride is introduced to the molybdenum of the nickel titanium soluble core which is exposed at open ends of the struts, and the resulting

molybdenum hexafluoride and xenon gases exhaust through the open ends. The open ends can then be sealed if desired.

[0036] After forming a strut central void, the method of manufacturing a stent 300 can further include filling the first strut central void with a drug or therapeutic agent. One or more of the strut central voids, or all the strut central voids, can be filled. In one example, a drug or therapeutic agent solution is drawn into the strut central void by capillary action, then the drug or therapeutic agent solution can be solidified. In one embodiment, the drug or therapeutic agent is introduced to the central void through perforations in the wall of the strut nickel titanium alloy layer, through which the drug or therapeutic agent is released after the stent is implanted in a patient. In another embodiment, the drug or therapeutic agent is introduced to the central void through an open end of the struts, which can then be sealed if desired. Perforations can then be formed in the strut nickel titanium alloy layer between the drug-filled central void and the exterior of the struts to allow release of the drug or therapeutic agent after implantation.

[0037] Drug, as defined herein, includes any drug, therapeutic agent, bioactive agent, or the like intended to affect the structure or any function of the body of man or other animals. The drug can include a polymer and a drug, or a drug alone. Exemplary drugs include any drug, therapeutic agent, or bioactive agent that can diffuse through a selected polymer, such as an antirestenotic drug (e.g., rapamycin, rapamycin analogue, or rapamycin derivative to prevent or reduce the recurrence or narrowing and blockage of the bodily vessel), an anti-cancer drug (e.g., camptothecin or other topoisomerase inhibitors), an antisense agent, an antineoplastic agent, an antiproliferative agent, an antithrombogenic agent, an anticoagulant, an antiplatelet agent, an antibiotic, an anti-inflammatory agent, a steroid, a gene therapy agent, an organic drug, a pharmaceutical compound, a recombinant DNA product, a recombinant RNA product, a collagen, a collagenic derivative, a protein, a protein analog, a saccharide, a saccharide derivative, a bioactive agent, a pharmaceutical drug, a therapeutic substance, a combination thereof, and the like.

[0038] A drug coating can be applied to the exterior of the stent if desired. The drug coating can include a polymer and a drug, or a drug alone. Exemplary polymers include any polymer compatible with a selected drug or therapeutic agent, i.e., polymers such as BioLinx[®] polymer, poly(vinyl alcohol), poly(ethylene-vinyl acetate), polyurethane, polycaprolactone, polyglycolide, poly(lactide-co-glycolide), poly(ethylene oxide), poly(vinyl pyrrolidone), silicone, an acrylic polymer, an acrylic and acrylonitrile copolymer, a latex

polymer, a thermoplastic polymer, a thermoset polymer, a biostable polymer, a biodegradable polymer, a blended polymer, a copolymer, combinations thereof, and the like.

[0039] It is important to note that **FIGS. 1-5** illustrate specific applications and embodiments of the invention, and are not intended to limit the scope of the present disclosure or claims to that which is presented therein. Upon reading the specification and reviewing the drawings hereof, it will become immediately obvious to those skilled in the art that myriad other embodiments of the invention are possible, and that such embodiments are contemplated and fall within the scope of the presently claimed invention.

[0040] While the embodiments of the invention disclosed herein are presently considered to be preferred, various changes and modifications can be made without departing from the spirit and scope of the invention. The scope of the invention is indicated in the appended claims, and all changes that come within the meaning and range of equivalents are intended to be embraced therein.

CLAIMS

1. A stent delivery system comprising:
a catheter;
a sheath disposed around the catheter; and
a stent disposed on the catheter, the stent forming a tubular body and comprising:
a first strut, the first strut having in transverse cross section a first strut nickel titanium alloy layer and a first strut nickel titanium soluble core, the first strut nickel titanium alloy layer being disposed around and immediately adjacent to the first strut nickel titanium soluble core; and
a second strut, the second strut having in transverse cross section a second strut nickel titanium alloy layer and a second strut nickel titanium soluble core, the second strut nickel titanium alloy layer being disposed around and immediately adjacent to the second strut nickel titanium soluble core, the second strut nickel titanium alloy layer being connected to the first strut nickel titanium alloy layer with a weld;
wherein the first strut nickel titanium alloy layer and the second strut nickel titanium alloy layer are made of a nickel titanium alloy, the first strut nickel titanium soluble core and the second strut nickel titanium soluble core are made of a nickel titanium soluble material, the weld is made of an alloy of the nickel titanium alloy and the nickel titanium soluble material, and the weld further connects the first strut nickel titanium soluble core and the second strut nickel titanium soluble core.
2. The system of claim 1 wherein the nickel titanium soluble material is molybdenum and the weld is a nickel, titanium, and molybdenum alloy.
3. The system of claim 1 wherein the nickel titanium soluble material is a molybdenum chromium alloy and the weld is a nickel, titanium, molybdenum, and chromium alloy.
4. The system of claim 1 wherein the nickel titanium soluble material is selected from the group consisting of chromium, molybdenum, iron, cobalt, mixtures thereof, and alloys thereof.

5. The system of claim 1 wherein the first strut and second strut are part of a single sinusoidal wire.

6. The system of claim 1 wherein the first strut nickel titanium alloy layer includes perforations between the first strut nickel titanium soluble core and the exterior of the first strut.

7. A stent forming a tubular body, the stent comprising:
a first strut, the first strut having in transverse cross section a first strut nickel titanium alloy layer and a first strut nickel titanium soluble core, the first strut nickel titanium alloy layer being disposed around and immediately adjacent to the first strut nickel titanium soluble core; and

a second strut, the second strut having in transverse cross section a second strut nickel titanium alloy layer and a second strut nickel titanium soluble core, the second strut nickel titanium alloy layer being disposed around and immediately adjacent to the second strut nickel titanium soluble core, the second strut nickel titanium alloy layer being connected to the first strut nickel titanium alloy layer with a weld;

wherein the first strut nickel titanium alloy layer and the second strut nickel titanium alloy layer are made of a nickel titanium alloy, the first strut nickel titanium soluble core and the second strut nickel titanium soluble core are made of a nickel titanium soluble material, the weld is made of an alloy of the nickel titanium alloy and the nickel titanium soluble material, and the weld further connects the first strut nickel titanium soluble core and the second strut nickel titanium soluble core.

8. The stent of claim 7 wherein the nickel titanium soluble material is molybdenum and the weld is a nickel, titanium, and molybdenum alloy.

9. The stent of claim 7 wherein the nickel titanium soluble material is a molybdenum chromium alloy and the weld is a nickel, titanium, molybdenum, and chromium alloy.

10. The stent of claim 7 wherein the nickel titanium soluble material is selected from the group consisting of chromium, molybdenum, iron, cobalt, mixtures thereof, and alloys thereof.

11. The stent of claim 7 wherein the first strut and second strut are part of a single sinusoidal wire.

12. The stent of claim 7 wherein the first strut nickel titanium alloy layer includes perforations between the first strut nickel titanium soluble core and the exterior of the first strut.

13. A method of manufacturing a stent comprising:

providing a first strut having in transverse cross section a first strut nickel titanium alloy layer and a first strut nickel titanium soluble core, the first strut nickel titanium alloy layer being disposed around and immediately adjacent to the first strut nickel titanium soluble core, the first strut nickel titanium alloy layer being made of a nickel titanium alloy, the first strut nickel titanium soluble core being made of a nickel titanium soluble material;

providing a second strut having in transverse cross section a second strut nickel titanium alloy layer and a second strut nickel titanium soluble core, the second strut nickel titanium alloy layer being disposed around and immediately adjacent to the second strut nickel titanium soluble core, the second strut nickel titanium alloy layer being made of the nickel titanium alloy, the second strut nickel titanium soluble core being made of the nickel titanium soluble material;

positioning the first strut adjacent to the second strut at a weld point;

at the weld point, melting portions of the first strut nickel titanium alloy layer, the first strut nickel titanium soluble core, the second strut nickel titanium alloy layer, and the second strut nickel titanium soluble core to form a weld pool including the nickel titanium alloy from the first strut nickel titanium alloy layer and the second strut nickel titanium alloy layer, the weld pool further including the nickel titanium soluble material from the first strut nickel titanium soluble core and the second strut nickel titanium soluble core; and

cooling the weld pool to form a weld connecting the first strut nickel titanium alloy layer to the second strut nickel titanium alloy layer.

14. The method of claim 13 wherein the weld further connects the first strut nickel titanium soluble core and the second strut nickel titanium soluble core.

15. The method of claim 13 further comprising removing the first strut nickel titanium soluble core to form a first strut central void.

16. The method of claim 15 further comprising filling the first strut central void with a drug.

17. The method of claim 15 wherein the first strut nickel titanium alloy layer includes perforations between the first strut nickel titanium soluble core and the exterior of the first strut, and the removing comprises removing the first strut nickel titanium soluble core through the perforations.

18. The method of claim 15 wherein the first strut nickel titanium alloy layer includes an open end to expose the first strut nickel titanium soluble core, and the removing comprises removing the first strut nickel titanium soluble core through the open end.

19. The method of claim 13 wherein the nickel titanium soluble material is molybdenum, the method further comprising contacting the first strut nickel titanium soluble core with xenon difluoride to form a first strut central void.

20. The method of claim 13 wherein the nickel titanium soluble material is molybdenum and the weld is a nickel, titanium, and molybdenum alloy.

21. The method of claim 13 wherein the nickel titanium soluble material is a molybdenum chromium alloy and the weld is a nickel, titanium, molybdenum, and chromium alloy.

22. The method of claim 13 wherein the nickel titanium soluble material is selected from the group consisting of chromium, molybdenum, iron, cobalt, mixtures thereof, and alloys thereof.

23. The method of claim 13 wherein the first strut and second strut are part of a single sinusoidal wire.

1/5





FIG. 1

2/5



2611

3/5







FIG. 3

4/5



5/5




FIG. 5

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2014/026984

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61F2/86

ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61F A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2012/067008 A1 (BIENVENU RYAN [US]) 22 March 2012 (2012-03-22) paragraphs [0031] - [0032], [0036]; figures 1-4	1-23
A	US 2011/251668 A1 (THOMPSON DUSTIN [US] ET AL) 13 October 2011 (2011-10-13) paragraphs [0041], [0046]; figures 1,10	1-23
A	US 2003/040772 A1 (HYODOH HIDEKI [JP] ET AL) 27 February 2003 (2003-02-27) paragraphs [0184] - [0187]	1-23



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

7 July 2014

Date of mailing of the international search report

14/07/2014

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Espuch, Antonio

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2014/026984

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2012067008 A1	22-03-2012	CN 103249437 A	14-08-2013
		EP 2616110 A1	24-07-2013
		JP 2013541971 A	21-11-2013
		US 2012067008 A1	22-03-2012
		WO 2012036890 A1	22-03-2012

US 2011251668 A1	13-10-2011	EP 2555717 A1	13-02-2013
		US 2011251668 A1	13-10-2011
		WO 2011126676 A1	13-10-2011

US 2003040772 A1	27-02-2003	US 7018401 B1	28-03-2006
		US 2003040771 A1	27-02-2003
		US 2003040772 A1	27-02-2003
		US 2003149475 A1	07-08-2003
		US 2009099643 A1	16-04-2009
		US 2012330398 A1	27-12-2012
		US 2014114389 A1	24-04-2014
